BioSpace: Biotech, Pharmaceutical and Clinical Research News
2 days ago · PBMs. Deep Dive: PBM Reform. In the battle over drug prices, one sector of the healthcare industry has risen above all the players as the boogeyman: pharmacy benefit managers. In this special edition of BioPharm Executive, BioSpace takes a deep dive into the lens now focused on PBMs’ business practices. September 18, 2024.
Approvals - BioSpace
Oct 30, 2024 · Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population. Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease. October 23, 2024.
Reports - BioSpace
Jul 24, 2024 · 2024 Q2 Job Market Report: More People Competing for Fewer Job Openings. For the second quarter of 2024, there were 25% fewer jobs posted live on BioSpace compared to the same quarter of 2023. The year-over-year job response rate …
Biopharma Business News - BioSpace
6 days ago · Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout. The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.
Latest News & Press Releases - BioSpace
5 days ago · Press Releases. Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers.
Clinical research - BioSpace
Nov 5, 2024 · Viking Touts Promising Phase I Weight Loss Data for Obesity Pill Candidate. Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy VK2735 exceeded expectations, with “class-leading” weight loss. Patients on 100-miligram doses of the pill lost 8.2% of their body weight after ...
Roche Inks Potential $1.8B Deal With Flare to Target ... - BioSpace
1 day ago · Tristan Manalac. iStock, Robert Way. With $70 million upfront and more than $1.8 billion on the line, Roche will gain access to Flare’s drug discovery engine to bolster the pharma’s oncology pipeline. Roche on Tuesday entered into a back-heavy oncology deal with Flare Therapeutics, paying $70 million upfront to discover and advance new ...
BioSpace Insights - BioSpace
Oct 29, 2024 · United States Pharmacopeia is recruiting expert volunteers from academia, industry, regulatory and healthcare to develop, revise and approve medicine, dietary supplement and food ingredient standards and solutions used in more than 150 countries to improve global public health. The volunteers will serve from 2025 to 2030.
Drug Development News - BioSpace
Nov 6, 2024 · Biogen, Vertex Heat Up IgAN Arena With Mid-Stage Readouts at ASN 2024. William Blair analyst Myles Minter in a Monday note to investors said that Vertex’s povetacicept “has maintained its potential to be a best-in-class asset” in the IgA nephropathy space and could become a “multibillion-dollar pipeline-in-a-drug product” for ...
FDA News: Approvals, Adcomms, Complete Response Letters and …
5 Accelerated Approvals Gone Wrong. Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market. However, recent years have seen a number of high-profile market withdrawals and failed confirmatory trials. October 14, 2024. ·.